Comments on: Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation

Comments on: Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation https://www.novumpr.nl/2016/12/19/vertex-announces-german-reimbursement-agreement-for-orkambi-lumacaftorivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-two-copie/?utm_source=rss&utm_medium=rss&utm_campaign=vertex-announces-german-reimbursement-agreement-for-orkambi-lumacaftorivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-two-copie NovumPR press releases Mon, 19 Dec 2016 09:51:00 +0000 hourly 1 https://wordpress.org/?v=6.8.3